
News|Videos|January 17, 2017
An Overview of the NeoMONARCH Trial in HR+/HER2- Breast Cancer
Author(s)Sara A. Hurvitz, MD
Sarah Hurvitz, MD, gives an overview of the neoMONARCH trial in hormone receptor-positive, HER2-negative breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















